68
EXAMINATION OF COAGULATION AND FIBRINOLYSIS MUDr. Pavel Maruna Dept. of Pathological Physiology 1st Faculty of Medicine

EXAMINATION OF COAGULATION AND FIBRINOLYSIS

  • Upload
    lore

  • View
    70

  • Download
    0

Embed Size (px)

DESCRIPTION

EXAMINATION OF COAGULATION AND FIBRINOLYSIS. MUDr. Pavel Maruna Dept. of Pathological Physiology 1st Faculty of Medicine. I. Physiology. Hemostasis. = The physiologic process protecting the integrity of the vascular system after tissue injury. Bleeding is halted to minimize blood loss. - PowerPoint PPT Presentation

Citation preview

Page 1: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

EXAMINATIONOF COAGULATION AND FIBRINOLYSIS

MUDr. Pavel MarunaDept. of Pathological Physiology1st Faculty of Medicine

Page 2: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

I.Physiology

Page 3: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Hemostasis= The physiologic process protecting the integrity of the vascular system after tissue injury.Bleeding is halted to minimize blood loss.

The hemostatic mechanisms include following steps:

1. Rest phase - To maintain blood in a fluid state while circulating within the vascular system

2. After injury - To arrest bleeding at the site of injury by formation of hemostatic plug

3. Restitution - To ensure the removal of the hemostatic plug when healing is complete

Page 4: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Hemostasis

Hemostasis is an integral part of

• stress reaction• inflammatory response

Protective role Pathophysiol. roleX

non-specific defense mechanism

thrombosis / embolism

atherosclerosis

Page 5: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Hemostasis as a physiological process must be:

1. Rapid

2. Localized

3. Reversible

Inappropriate hemostasis:

- Thrombosis / embolism

- DIC

- bleeding / blood loss

Hemostasis

Page 6: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Hemostasis

Plasmacoagulation

system

Vessel wall

Platelets

Endothelium

Page 7: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Antithrombotic Properties

Anti-platelet activities:

– Covers highly thrombogenic basement membrane

– Uninjured endothelium does not bind platelets

– PGI2 and NO from endothelium inhibit platelet binding

– ADPase counters the platelet aggregating effects of

ADP

Endothelium

Page 8: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Anticoagulant activities:

– Heparin-like molecules ... activate anti-thrombin III

(inactivates active proteases)

– Thrombomodulin ... changes specificity of

thrombin (activates protein C , which inactivates factors

Va and VIIIa

– tPA ... activates fibrinolysis via plasminogen to plasmin

Antithrombotic Properties

Endothelium

Page 9: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

• Synthesis of von Willebrand factor

• Release of tissue factor

• Production of PAI (plasminogen activator inhibitors)

• Membrane phospholipids bind and facilitate activation of clotting factors via Ca bridges

Endothelium

Prothrombotic Properties

Page 10: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Antithrombogenic Thrombogenic

Vessel injury

(Favors fluid blood) (Favors clotting)

Endothelium

Page 11: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Vasoconstriction

Primary hemostasis

Secondary hemostasis

Fibrinolysis

Page 12: EXAMINATION OF COAGULATION AND FIBRINOLYSIS
Page 13: EXAMINATION OF COAGULATION AND FIBRINOLYSIS
Page 14: EXAMINATION OF COAGULATION AND FIBRINOLYSIS
Page 15: EXAMINATION OF COAGULATION AND FIBRINOLYSIS
Page 16: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrinogen FibrinThrombin

Prothrombin

XaVa

VIIa

TF

Extrinsic Pathway

IXa

VIIIa

XIa

XIIa

Intrinsic pathway

XIIIa

Soft clot

Fibrin

Hard clot

V

VIII

Coagulation

Page 17: EXAMINATION OF COAGULATION AND FIBRINOLYSIS
Page 18: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

• Enzymatic cascade (amplification)

• Several serine proteases

• Produced by liver (most)

• Require vitamin K (several)

• 3 protein cofactors (not enzymes)

• Requires Ca 2+

• Reversible (via production of plasmin)

Coagulation

Page 19: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Coagulation

Page 20: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Coagulation

Page 21: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrinogen Fibrin

Thrombin

Coagulation

Page 22: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrinogen Fibrin

Thrombin

Prothrombin

XaVa

Coagulation

Page 23: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrinogen Fibrin

Thrombin

Prothrombin

XaVa

VIIa

TF

Coagulation

Extrinsic Pathway

Page 24: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrinogen Fibrin

Thrombin

Prothrombin

XaVa

VIIa

TF

IXa

VIIIa

XIa

XIIa

Extrinsic Pathway

Intrinsic pathway

Coagulation

Page 25: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrinogen FibrinThrombin

Prothrombin

XaVa

VIIa

TF

IXa

VIIIa

XIa

XIIa

XIIIa

Soft clot

Fibrin

Hard clot

Extrinsic Pathway

Intrinsic pathway

Coagulation

Page 26: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrinogen FibrinThrombin

Prothrombin

XaVa

VIIa

TF

IXa

VIIIa

XIa

XIIa

XIIIa

Soft clot

Fibrin

Hard clot

V

VIII

Extrinsic Pathway

Intrinsic pathway

Coagulation

Page 27: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Thrombin (IIa)

Prothrombin (II)

Xa

VIIa

TF

IXa

Revised tissue factor pathway

IX

New: Production of IXaInteraction of intrinsic and extrinsic pathways

Extrinsic Pathway

Page 28: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Thrombin (IIa)

Prothrombin (II)

Xa

VIIa

TF

IXa

New: TFPI = Tissue Factor Pathway Inhibitor... inhibition of Xa and VIIa

IX

TFITFPI

Revised tissue factor pathway

Page 29: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Prothrombin (II)

Xa

VIIa

TF

IXa

New: TFPI = Tissue Factor Pathway Inhibitor... inhibition of Xa and VIIa

IX

TFITFPI

Revised tissue factor pathway

Kunitz-type protease inhibitor (kringles)34 and 41 kD forms in plasma (C-term truncation)

Activities:- direct inhibition of Xa- inhibition VIIa-TF complex in a [Xa]-dependent manner- bounding to LDL, HDL and Lp (a)

~10% present in platelets (endothelium also)

Page 30: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Production of IXa

Production of small amounts of thrombin (IIa)

Net results:

No or only little fibrin formed!

Revised tissue factor pathway

Page 31: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

• VIIa forms via binding of VII to TF• VIIa activates some XXa• Xa converts a small amount of II to IIa; this thrombin is

used to produce small amts of VIIIa and Va• As the concentration of TF-VIIa-Xa-IIa increases, TFPI

inactivates this complex stopping further production of thrombin.

• IXa, with VIIIa (produced as above), produces Xa; this Xa with Va produces new thrombin; this thrombin produces more VIIIa and Va and now we get lots of thrombin and fibrin.

Revised tissue factor pathway

Page 32: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrinogen FibrinThrombin

Prothrombin

XaVa

VIIa

TF

IXa

VIIIa

XIIIa

Soft clot

Fibrin

Hard clot

V

VIII

IX

Revised tissue factor pathway

Page 33: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Thrombin (IIa)

VIII

VIIIa

V

Va

Revised tissue factor pathway

Page 34: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Role of vitamin K

Factors II, VII, IX, X, proteins C and Srequire a post-translationalmodification before their activation

This PTM requires vitamin K

This PTM involves the addition of a COO- to certain Glu residues in the clotting factors

resulting in the formation of several g-carboxy glutamates

Page 35: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Role of vitamin K

Page 36: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Physiologic inhibitors of coagulation

• Antithrombin III – SERPIN

• Activated Protein C + protein S– Inactivates Va and VIIIa (via proteolysis)– mutation: Factor V Leiden (APC resistance)

• Thrombomodulin– Binds to thrombin– Decreases ability to produce fibrin– Increases ability to activate Protein C

Page 37: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

• Vitamin K antagonists(in vivo only)

• Ca chelators(in vitro only)– EDTA– Citrate– Oxalate

• Heparin

(in vivo and in vitro)

Non-physiologic inhibitors of coagulation

Page 38: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrinolysis

... Clot removal

Page 39: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrin Fibrin Split Products (FSP)Plasmin

Fibrinolysis

Page 40: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrin Fibrin Split Products (FSP)Plasmin

Plasminogen

tPA

Fibrinolysis

uPAbacterial enzymes

(streptokinase)

Page 41: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrin Fibrin Split Products (FSP)Plasmin

Plasminogen

tPA

Fibrinolysis

Inhibitors of fibrinolysis

PAI

a2-antiplasmin

... SERPINs

Page 42: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrinolysis

Page 43: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

II.Pathology

Page 44: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Coagulopathies

AcquiredCongenital

Page 45: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Coagulopathies

AcquiredCongenital

Hemophilia A ... f VIIIHemophilia B ... f IXHemophilia C ... f XIDys- / A- fibrinogenemiaF V defic. (parahemophilia)F XIII defic.APC resistance

Page 46: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Coagulopathies

AcquiredCongenital

Liver proteosynthesisVitamin K defic.

- obstructive icterus- intestin. resorption

Anticoagulant therapy- Dicumarol- Heparin

Page 47: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Vasculopathies

AcquiredCongenital

Purpura Henoch-SchönleinScorbutSteroid purpuraPurpura simplex and senilis

Mb. Rendu-Osler-Weber= hereditary hemorrhagic teleangiectasiaAD, TGFbeta1 rec.

Ehlers-Danlos Sy.= defects in collagen synthesis

Page 48: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Genetic examination

Hemophilia A X-linked recessive

1 : 10 000

Page 49: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Clinical signs

Hemophilia Large hemorrhage after a small injury

Arthral hemorrhage

Secondary arthropathy

Page 50: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Clinical signs

Thrombocytopenia Petechiae, pigmentation

Page 51: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Clinical signs

Henoch-Schonlein

Page 52: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Clinical signs

F XIII deficiency Late bleeding

Keloid scarring

Page 53: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Clinical signs

Deep venous thrombosis

Pulmonary embolism

Page 54: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

III.Diagnostics and

monitoring

Page 55: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Prothrombin Time (Quick test)

Principle: Stimulation of extrinsic (main) coag. system

Citrate plasma ... add TF (in excesive amount) + CaCl2 ... fibrin fibre

Normal: PT = 12 - 15 sINR = (PTP / PTN)ISI

ISI = international index of sensitivity of used thromboplastin (commonly > 1)

Prolongation: defic. vit. K dep. FII, VII, X, FbgUsage: screening, monitoring of oral anticoagulants,

liver proteosynthesis

Normal range INR 0,8 - 1,2Therapeutic range INR = 2,5 - 4,5Surgery INR < 1,6

Page 56: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

APTT, Activated partial thromboplastin time

Principle: Stimulation of intrinsic (contact) way of coag. system

Citrate plasma ... add contact activator (e. g. kaolin) + CaCl2 ... fibrin fibre

Page 57: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

APTT, Activated partial thromboplastin time

Principle: Stimulation of intrinsic (contact) way of coag. system

Citrate plasma ... add contact activator (e. g. kaolin) + CaCl2 ... fibrin fibre

Normal: APTT = 27 - 35 s

Prolongation: defic. of VII, V, X, XII, VIII, XI, IX (hemophilia A,B,C), Fbg, FDP

Shortening: prothrombotic statusUsage: screening, diagnostics of coagul. deficits,

monitoring of heparin therapy

Therapeutic range 1,2 - 2,5 x

Page 58: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Lee-White test

Cloting time of whole blood

Whole blood without anticoagulants (CaCl2) ... polystyrene or glass tube, 37°C ... spontaneous stimulation of intrinsic

Normal: 4 - 10 min.

Usage: Basic, rough orientation in acute status

Page 59: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Thrombin Time

Whole blood without anticoagulants (CaCl2) ... add thrombin in standard amount, 37°C ... fibrin fibre

Normal: 12 - 14 s

Prolongation: Fbg (acute stage of DIC)antithrombinsfibrinolysis

Usage: DICmonitoring of fibrinolytic therapy

Page 60: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Fibrinogen, Fbg

Normal plasma levels = 2 - 4 g /lFunctional of immunological detection

High: InflammationDMSmoking

Low: Low synthesis (congenital or liver function)Consumption (DIC)

HypofibrinogenemiaDysfibrinogenemia

Page 61: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

FDP

Total degradation products of fibrin(-ogen)

ELISA or aglutination semiquantitative methods

High: Recent coagulation activity(thrombo/embolism, bleeding, surgery, DIC ...)

High senzitivity, low specificity

Page 62: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Paracoagulation tests (Ethanol, Protamin)

Principle: Ethanol catalyzes conversion of fibrin monomers + PDP fibrin polymers

Low senzitivity and specificity

Usage: 1st stage of DIC

Page 63: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Duke test

Duke, 1910Estimation of bleeding timeTime of spontaneous cutoff of bleeding after

standard puncture to auricle of ear

Limits: 2 - 5 min., or 4 - 8 min. (depends od methods)

Prolongation - Disturbance of primary hemostasis:Plt < 20 000 or Plt dysfunction, vW

disease

Page 64: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Rumpel - Leede test

Capillary resistance

Number of petechia on forearm (area 4 x 4 cm) after a standard pressure (ruff 10,5 kPa for 10 min.) or after underpressure (Brown, 1949)

Limits: > 5 petechia ... higher capillary fragility(e.g. hereditary purpura Weber-Rendu-Osler)

Page 65: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Presumable results

Diagnosis Plt Duke APTT Quick TT

Thrombocytopenia N N N

Hemophilia A N N N N

Hemophilia B N N N N

Hemophilia C N N N N

vWd N N / N N

Page 66: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Presumable results

Diagnosis Plt Duke APTT Quick TT

F V defic. N N N

F II defic. N N N N

F VII defic. N N N N

Warfarin / vit. K def. N N N

Heparin i. v. N N / N /

Heparin s. c. N N N N N

Page 67: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Presumable results

Diagnosis Plt Ethan APTT Quick TT

DIC 1st stage + N

DIC 2nd stage -

Page 68: EXAMINATION OF COAGULATION AND FIBRINOLYSIS

Quick time, INR 0,8 - 1,2

APTT 27-35 s

Thrombin time 12 - 14 s

Fibrinogen 2 - 4 g/l

Antithrombin III > 70%

Ethanol test neg.

D-dimers (FDP) neg.

Quick time, INR 0,8 - 1,2

APTT 27-35 s

Thrombin time 12 - 14 s

Fibrinogen 2 - 4 g/l

Antithrombin III > 70%

Ethanol test neg.

D-dimers (FDP) neg.

Standard tests in General Faculty Hospital